Filing Details

Accession Number:
0000899243-20-027918
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-09 17:23:58
Reporting Period:
2020-10-07
Accepted Time:
2020-10-09 17:23:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1699848 Franco Valle C/O Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2000
San Francisco CA 94104
Senior Vice President, Finance No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-07 5,000 $7.24 5,444 No 4 M Direct
Common Stock Disposition 2020-10-07 5,444 $75.08 0 No 4 S Direct
Common Stock Acquisiton 2020-10-08 5,199 $7.24 5,199 No 4 M Direct
Common Stock Disposition 2020-10-08 5,199 $74.85 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-10-07 5,000 $0.00 5,000 $7.24
Common Stock Stock Option (Right to Buy) Disposition 2020-10-08 5,199 $0.00 5,199 $7.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,419 2028-05-06 No 4 M Direct
29,220 2028-05-06 No 4 M Direct
Footnotes
  1. Represents the weighted average sale price of the shares sold from $74.9701 to $75.3901 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2.
  2. Represents the weighted average sale price of the shares sold from $74.77 to $74.95 per share.
  3. The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer.